|
VRK3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62447832963153E-12 |
| Normal-vs-Stage2 |
1.02310382388282E-11 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62436730732907E-12 |
| Stage1-vs-Stage2 |
7.714000E-01 |
| Stage1-vs-Stage3 |
2.819000E-01 |
| Stage1-vs-Stage4 |
1.693880E-02 |
| Stage2-vs-Stage3 |
3.087600E-01 |
| Stage2-vs-Stage4 |
1.409660E-02 |
| Stage3-vs-Stage4 |
1.582970E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62447832963153E-12 |
| Normal-vs-AfricanAmerican |
7.47770001474635E-09 |
| Normal-vs-Asian |
1.64912528077821E-12 |
| Caucasian-vs-AfricanAmerican |
5.463600E-01 |
| Caucasian-vs-Asian |
9.808000E-01 |
| AfricanAmerican-vs-Asian |
4.929400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.33066907387547E-16 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
8.592200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
<1E-12 |
| Normal-vs-Age(41-60Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(61-80Yrs) |
1.6242562850266E-12 |
| Normal-vs-Age(81-100Yrs) |
3.166000E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.306400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.009200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.090600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.128200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.894600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.864200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.551200E-04 |
| Classical-VS-Follicular |
2.200800E-01 |
| Classical-VS-Other |
2.301800E-01 |
| Classical-VS-Normal |
<1E-12 |
| Tall-VS-Follicular |
3.598700E-04 |
| Tall-VS-Other |
9.318600E-01 |
| Tall-VS-Normal |
1.62436730732907E-12 |
| Follicular-VS-Other |
2.282000E-01 |
| Follicular-VS-Normal |
1.94700000566428E-09 |
| Other-VS-Normal |
7.318000E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.62447832963153E-12 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
2.34789999999929E-05 |
|
|
